Home >Current Issue

Volume: 9, Issue: 8, August, 2019
DOI: 10.7324/JAPS.2019.90801



Research Article

Short chain linear and cyclic cationic peptide designed from cecropin B: Synthesis and anticancer activity

Ravi Dutt Sharma1, Jainendra Jain2, Ratan Lal Khosa1

  Author Affiliations


Abstract

In the present work, we have designed short chain α-helical linear and cyclic peptide from cecropin B having same charge, hydrophobicity, and helicity. The designed compounds were synthesized by using solution phase method. Elucidation of structure of newly synthesized peptides was done by proton nuclear magnetic resonance, Carbon-13 nuclear magnetic resonance, Fourier-transform infrared spectroscopy, Fast atom bombardment mass spectrometry, and elemental analysis. Furthermore, the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltratrazolium bromide assay was performed for cytotoxicity of synthesized compounds against Dalton’s lymphoma ascites (DLA), Ehrlich’s ascites carcinoma (EAC), and Michigan Cancer Foundation-7 cell lines using 5-FU as a reference compound. Biological evaluation showed that short chain cyclicpeptides were more potent than linear peptides against EAC and DLA cell lines.

Keywords:

Cecropin B, cationic peptides, cytotoxic activity, DLA cell lines.



Citation: Sharma RD, Jain J, Khosa RL. Short chain linear and cyclic cationic peptide designed from cecropin B: Synthesis and anticancer activity. J Appl Pharm Sci, 2019; 9(08):001–010.


Copyright: The Author(s). This is an open access article distributed under the Creative Commons Attribution Non-Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

Ben-Ishai D, Berger A. Cleavage of N-Carbobenzoxy groups by dry hydrogen bromide and hydrogen chloride. J Org Chem, 1952; 17(12):1564-70. https://doi.org/10.1021/jo50012a002

Bodanzsky M, Bodanzsky A. The practice of peptide synthesis. Springer-Verlag, New York, NY, 1984.

Brooks SA, Lomax-Browne HJ, Carter TM, Kinch CE, Hall DM. Molecular interactions in cancer cell metastasis. Acta Histochem, 2010; 112(1):3-25. https://doi.org/10.1016/j.acthis.2008.11.022

Bush JA, Li G. Cancer chemoresistance: the relationship between p53 and multidrug transporters. Int J Cancer, 2002; 98(3):323-30. https://doi.org/10.1002/ijc.10226

Chou HT, Kuo TY, Chiang JC, Pei MJ, Yang WT, Yu HC, Lin SB, Chen SW. Design and synthesis of cationic antimicrobial peptides with improved activity and selectivity against Vibrio spp. Int J Antimicrob Agents, 2008; 32(2):130-38. https://doi.org/10.1016/j.ijantimicag.2008.04.003

Dahiya R, Kumar A, Gupta R. Synthesis, cytotoxic and antimicrobial screening of a proline-rich cyclopolypeptide. Chem Pharm Bull, 2009; 57(2):214-17. https://doi.org/10.1248/cpb.57.214

Dahiya R, Mourya R, Agrawal SC. Synthesis and antimicrobial screening of peptidyl derivatives of bromocoumarins/methylimidazoles. Afr J Pharm Pharmacol, 2010; 4(5):214-25.

Dahiya R, Pathak D. First total synthesis and biological evaluation of halolitoralin A. J Serb Chem Soc, 2007; 72(2):101-07. https://doi.org/10.2298/JSC0702101D

Dahiya R, Sharma RD. Synthesis and bioactivity of a novel cyclic hexapeptide from Stellaria Delavayi. Eur J Sci Res, 2008; 21(2):277-87.

Dennison SR, Whittaker M, Harris F, Phoenix DA. Anticancer alpha-helical peptides and structure/function relationships underpinning their interactions with tumour cell membranes. Curr Protein Pept Sci, 2006; 7(6):487-99. https://doi.org/10.2174/138920306779025611

Donnelly JG. Pharmacogenetics in cancer chemotherapy: balancing toxicity and response. Ther Drug Monit, 2004; 26(2):231-35. https://doi.org/10.1097/00007691-200404000-00026

Harris F, Dennison SR, Singh J, Phoenix DA. On the selectivity and efficacy of defense peptides with respect to cancer cells. Med Res Rev, 2013; 33(1):190-234. https://doi.org/10.1002/med.20252

Hoskin DW, Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta Biomembr, 2008; 1778(2):357-75. https://doi.org/10.1016/j.bbamem.2007.11.008

Huang Y, Feng Q, Yan Q, Hao X, Chen Y. Alpha-helical cationic anticancer peptides: a promising candidate for novel anticancer drugs. Mini Rev Med Chem, 2015; 15(1):73-81. https://doi.org/10.2174/1389557514666141107120954

Hui L, Leung K, Chen HM. The combined effects of antibacterial peptide cecropin A and anti-cancer agents on leukemia cells. Anticancer Res, 2002; 22(5):2811-16.

Kosaku N, Shigeyuki T, Nobuo I. Modified benzyloxycarbonyl group for protection of ε-amino groups of lysine. Bull Chem Soc Jpn, 1970; 43(6):1883-85. https://doi.org/10.1246/bcsj.43.1883

Kreeger PK, Lauffenburger DA. Cancer systems biology: a network modeling perspective. Carcinogenesis, 2009; 31(1):2-8. https://doi.org/10.1093/carcin/bgp261

Liberio MS, Joanitti GA, Fontes W, Castro M.S. Anticancer peptides and proteins: a panoramic view. Protein Pept Lett, 2013; 20(4):380-91. https://doi.org/10.2174/092986613805290435

Mader JS, Hoskin DW. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs, 2006; 15(8):933-46. https://doi.org/10.1517/13543784.15.8.933

Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta Rev Cancer, 2010; 1805(1):105-17. https://doi.org/10.1016/j.bbcan.2009.11.002

Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VHC, Groom AC, Chambers AF. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat, 2003; 82(3): 199-206. https://doi.org/10.1023/B:BREA.0000004377.12288.3c

Riedl S, Zweytick D, Lohner K. Membrane-active host defense peptides-challenges and perspectives for the development of novel anticancer drugs. Chem Phys Lipids, 2011; 164(8):766-81. https://doi.org/10.1016/j.chemphyslip.2011.09.004

Srisailam S, Arunkumar AI, Wang W, Yu C, Chen HM. Conformational study of a custom antibacterial peptide cecropin B1: implications of the lytic activity. Biochim Biophys Acta Protein Struct Mol Enzymol, 2000; 1479(1-2):275-85. https://doi.org/10.1016/S0167-4838(00)00008-X

Sung SY, Hsieh CL, Wu D, Chung LW, Johnstone PA. Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer 2007; 31(2):36-100. https://doi.org/10.1016/j.currproblcancer.2006.12.002

Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis 2010; 31(1):100-10. https://doi.org/10.1093/carcin/bgp263

Zelezetsky I, Tossi A. Alpha-helical antimicrobial peptides- using a sequence template to guide structure-activity relationship studies. Biochim Biophys Acta Biomembr, 2006; 1758(9):1436-49. https://doi.org/10.1016/j.bbamem.2006.03.021

Article Metrics